A tailored course, built for your situation
Production-Grade AI in Pharmaceutical R&D Operations for Regulated Industries
A 12-module implementation blueprint for compliant, scalable AI systems in drug development
The situation this course is for
Teams invest in AI prototypes that cannot scale, meet regulatory standards, or integrate into existing GxP workflows, leading to wasted resources and delayed innovation.
Who this is for
Business and technology professionals in pharmaceutical R&D, regulatory affairs, data science, or digital transformation roles seeking to deploy AI systems that are auditable, reproducible, and operationally sustainable.
Who this is not for
This course is not for entry-level data science students or those seeking theoretical AI overviews without implementation focus.
What you walk away with
- Architect AI systems compliant with 21 CFR Part 11, Annex 11, and ALCOA+ principles
- Implement validation protocols for machine learning models in clinical and non-clinical settings
- Design governance frameworks for AI model lifecycle management in regulated environments
- Integrate AI pipelines into existing R&D data infrastructure with audit readiness
- Deploy risk-based monitoring and change control for sustained regulatory compliance
The 12 modules (with all 144 chapters)
- Introduction to AI in regulated pharmaceutical contexts
- Regulatory landscape: FDA, EMA, and ICH guidelines
- Defining production-grade vs. experimental AI
- Key stakeholders in AI governance
- Risk classification of AI applications
- Data integrity in AI systems (ALCOA+)
- GxP implications for model development
- Change control and audit readiness
- Documentation standards for AI
- Validation lifecycle overview
- Ethical considerations in drug development AI
- Course roadmap and implementation goals
- Layered architecture for regulated AI
- Data provenance and lineage tracking
- Containerization and environment control
- Version control for models and data
- Secure deployment patterns
- Access control and role-based permissions
- Audit logging requirements
- Integration with LIMS and ELN systems
- Cloud vs. on-premise considerations
- Disaster recovery and business continuity
- Scalability under GxP constraints
- Architecture review and sign-off processes
- Data quality frameworks in pharmaceutical AI
- Raw vs. processed data handling
- Metadata standards for AI training sets
- Data anonymization and privacy compliance
- Reference data management
- Data lifecycle controls
- Handling missing or corrupted data
- Data reconciliation procedures
- Audit trails for data transformations
- Data retention and archiving
- Third-party data validation
- Data governance board coordination
- Phased approach to model development
- Requirement specification for AI use cases
- Algorithm selection under regulatory scrutiny
- Training data curation and bias mitigation
- Model training documentation
- Hyperparameter tracking and reproducibility
- Model performance metrics
- Overfitting and generalization risks
- Model versioning strategies
- Development environment controls
- Code review in regulated AI
- Handoff to validation team
- Validation strategy for AI systems
- Developing a validation plan (VP)
- Installation Qualification (IQ) for AI
- Operational Qualification (OQ) for models
- Performance Qualification (PQ) in live environments
- Challenge datasets and edge case testing
- Model drift detection and response
- Validation documentation standards
- Revalidation triggers and schedules
- Third-party model validation
- Audit preparation for AI validation
- Validation sign-off and release
- AI in IND, NDA, and MAA submissions
- Common Technical Document (CTD) integration
- Model summary for regulators
- Transparency and explainability requirements
- Documentation of training data sources
- Algorithmic bias assessment reports
- Model limitations disclosure
- Change history for submitted models
- Post-approval monitoring plans
- Responses to regulatory queries on AI
- Internal review process for submissions
- Cross-functional coordination for filings
- Change control process overview
- Impact assessment for AI modifications
- Classification of change severity
- Change request documentation
- Testing requirements for updates
- Rollback procedures for AI systems
- Version synchronization across environments
- Communication of changes to stakeholders
- Post-implementation review
- Audit trail updates for changes
- Automated change detection
- Periodic review of change logs
- Real-time model performance dashboards
- Automated alerting for anomalies
- Model drift and data drift detection
- Scheduled retraining protocols
- User feedback integration
- Incident reporting for AI failures
- Root cause analysis for model issues
- Maintenance windows and downtime planning
- Backup and recovery for model states
- Performance benchmarking over time
- Resource utilization monitoring
- End-of-life planning for AI systems
- AI governance committee formation
- Roles and responsibilities in AI oversight
- Risk-based governance tiers
- Policy development for AI use
- Compliance auditing of AI systems
- Ethics review board integration
- Vendor oversight for third-party AI
- Training and competency requirements
- KPIs for AI governance effectiveness
- Escalation pathways for issues
- Regulatory intelligence integration
- Continuous improvement of governance
- AI in target identification and validation
- Predictive modeling in preclinical studies
- Patient recruitment optimization
- Clinical trial design assistance
- Adverse event prediction models
- Real-world evidence integration
- Manufacturing process optimization
- Quality control with computer vision
- Supply chain forecasting with AI
- Regulatory writing automation
- Cross-functional workflow mapping
- User adoption strategies
- Vendor selection criteria for AI tools
- Due diligence for AI software providers
- Contractual requirements for compliance
- Audit rights and transparency clauses
- Data ownership and IP considerations
- Validation support from vendors
- Ongoing performance monitoring
- Incident response coordination
- Exit strategies and data portability
- Multi-vendor ecosystem management
- Regulatory alignment across vendors
- Vendor governance reporting
- AI center of excellence formation
- Standardization of tools and platforms
- Knowledge sharing and documentation
- Training programs for AI literacy
- Portfolio management of AI initiatives
- Resource allocation and prioritization
- Measuring ROI of AI projects
- Change management at scale
- Regulatory forecasting for AI expansion
- Global compliance harmonization
- Lessons learned and continuous improvement
- Strategic roadmap for enterprise AI
How this maps to your situation
- You're leading an AI initiative that must pass internal audit
- You're integrating third-party AI tools into clinical workflows
- You're scaling pilot models to production under GxP
- You're preparing AI documentation for regulatory submission
Before vs. after
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 45, 60 minutes per module, designed for steady progress alongside professional responsibilities.
How this compares to the alternatives
Unlike academic courses or vendor-specific training, this program focuses on cross-platform, regulation-first implementation practices tailored to pharmaceutical R&D operations.
Frequently asked
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.